Rani Therapeutics Holdings, Inc. (RANI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

7.15

-0.31

(-4.16%)

At close: 04:00PM EDT

7.05

-0.10

(-1.40%)

After hours:

05:50PM EDT

Loading interactive chart…

GuruFocus.com
Rani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates
Insights into Rani Therapeutics' First Quarter Results and Future Clinical Endeavors
GlobeNewswire
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 - SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral d
Simply Wall St.
Favourable Signals For Rani Therapeutics Holdings: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...